Cole D R, Pung J, Pung F, Cole D F
Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):68-70.
A case of myelofibrosis successfully treated by the use of splenectomy has been reported. The feeling of the authors is that splenectomy should be considered at a much earlier stage of the disease, when the patient is a better risk with a longer survival. We see no valid physiological reasoning for leaving a spleen in, which is valueless to the patient in addition to causing multiple side effects, directly and indirectly from its size and overactivity. This is especially true when attempts to reduce the size have potential hazards, none are completely effective and when the physiological necessity for this reticulo endothelial site seems to be unnecessary. Perhaps it would be of greatest value if all cases of myelofibrosis should be seen at the inception and throughout by the hematological and surgical service together.
已有报道称一例骨髓纤维化患者通过脾切除术成功治愈。作者认为,在疾病的更早阶段就应考虑脾切除术,此时患者风险较小,生存期更长。我们认为保留脾脏没有合理的生理学依据,脾脏对患者毫无价值,还会直接或间接因其大小和功能亢进导致多种副作用。当试图缩小脾脏大小存在潜在风险、没有方法能完全有效且似乎没有保留这个网状内皮部位的生理必要性时,情况尤其如此。或许,如果所有骨髓纤维化病例从一开始就由血液科和外科共同诊治,可能会有最大价值。